Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Investment Chat Board Lawsuits -- Ignore unavailable to you. Want to Upgrade?

To: Jeffrey S. Mitchell who wrote (6915)	12/30/2004 7:25:58 AM
From: scion	Respond to of 12465

Davidson also hyped GeneMax without disclosing he was the CFO and a founding shareholder with almost 1.5 million shares. I'd say that was a clear violation of SEC regulations... ...it is easy to imagine that GeneMax could be worth $80 per share, or even $800 per share. I don't know what a cure for cancer would be worth. But it could be worth a lot. GeneMax could grow a hundredfold in value. Or maybe a thousandfold.

To: Jeffrey S. Mitchell who wrote (6915)	12/30/2004 7:30:25 AM
From: scion	Respond to of 12465

Who Is James Dale DAVIDSON? August 2, 2002 Stocklemon reports on GeneMax (OTC BB:GMXX) When Bad Things Happen To Good People stocklemon.com James DAVIDSON is one of largest individual shareholder in Genemax with holdings of 1,250,000 shares. According to Genemax’s website, he is also the Chief Financial Officer and Secretary of the Company. It appears to Stocklemon that Mr. DAVIDSON is quite an erudite gentleman with a résumé that would impress even the most harshest critic. He is a publisher, lecturer, and director of many public and private companies. Stocklemon is of the belief that Mr. DAVIDSON should add to his list of credentials the title of “stock promoter”. Mr. DAVIDSON is the founder of Agora Publishing which publishes reports on investment opportunities. Mr. DAVIDSON profiled IGSTF in one of his past newsletters. Please click on the link below to see some of the bold claims made by Mr. DAVIDSON. Stocklemon has never read a more aggressive report, that sells the dream more, than the one presented by Mr. DAVIDSON. Stocklemon suggests that the regulators take a look at the statements made by his newsletters. agora-inc.com He is currently doing the same promotion with Genemax. According to his report, “As I write this, we are also offering a couple of absolutely stunning medical and biotech breakthrough opportunities to investors. One of them is a breathtaking gene therapy that offers incredible hope for cancer patients. n animal trials, two-thirds of mice injected with human lung cancer tumors with the biomass equivalent of basketballs were cured using this treatment. And this technology has already been hailed in Nature Biotech, one of the most prestigious journals in the world. GeneMax Pharmaceuticals has already turned down several offers to go public that management deemed inadequate given the company's huge potential. It is currently entertaining a new proposal, however, of enormous potential benefits to Strategic Opportunities initial investors.” agora-inc.com STO/StartTheProfits/ By the way, we at Stocklemon were wondering - just how does a mouse have a tumor the size of a basketball? In the same newsletter, Mr. DAVIDSON discusses another stock that he is involved in called BEVsystems International, which currently trades at .19 cents. He writes about BEVsystems International as follows, “BEVsystems International is poised to skyrocket to similar valuations. I'm not at liberty to disclose the exciting endorsement agreement and takeout financing arrangements under way, but I can assure you that our ground floor investors stand to make exponential profits. And it's just one of several life-changing and wealth-building options for my select group of "adventure" investors.” agora-inc.com STO/StartTheProfits/ Where is the Disclosure? What seems to be missing in the above paragraph about BEVsystems International is the disclosure statement which states Mr. DAVIDSON’s relationship with BEVsystems International. Writing a newsletter carries responsibilities to your readers. Stocklemon does not believe that Mr. DAVIDSON has fulfilled these responsibilities. Just last week, Mr. DAVIDSON hosted an investment seminar in San Francisco awaionline.com. Stocklemon is curious to know if Mr. DAVIDSON presented Genemax as one of his “serious profit opportunities”. If he did, did he properly disclose his relationship to the company? We believe that this could present a serious conflict of interests that should be addressed by Mr. DAVIDSON. Below are three other stocks that James DAVIDSON was and/or is involved in: 1. BEVS- .19 cents bigcharts.marketwatch.com chart/quickchart.asp?symb=bevs&sid=0 &o_symb=bevs 2. ALIAF (Pink Sheets) - .89 cents finance.yahoo.com 3. MIVT- .32 cents finance.yahoo.com Offshore Companies It is Stocklemon’s experience that whenever there are large amounts of offshore holders in a company, there is a higher propensity for the stock to go lower. There are many reasons why offshore accounts are used but notice two common denominators, (a) none of these accounts are in the names of individuals; and (b) many are located in known tax and security havens. The following are a list of some of the offshore holders: Latitude 32 Holdings Ltd. Shareholder Mareva House 4 George Street Nassau, Bahamas Aberdeen Holdings Limited Shareholder 16 Market Street Belize City, Belize Calista Capital Corp. P.O. Box W-961 St. Johns Antigua West Indies (1) Common Stock Spartan Asset Group P.O. Box W-960 St. Johns Antigua West Indies 14 Pacific Rim Financial Inc. C/o Arundel House 31A St. James Square London SW1Y 4JR United Kingdom (1) Common Stock Eastern Capital Corp. C/o Northbrook Farm Bentley Farnham Hampshire GU10 5EU United Kingdom (1) Common Stock Eiger Properties Inc. C/o P.O. Box CH-4002 Basel, Switzerland (1) Common Stock Rising Sun Capital Corp. 96 Front Street Hamilton HM12 Bermuda

To: Jeffrey S. Mitchell who wrote (6915)	12/30/2004 8:41:27 AM
From: scion	Read Replies (1) \| Respond to of 12465

Industry ban for Valentine Barred for life by OSC pact, ex-chairman of brokerage can't trade stocks for five years Wojtek Dabrowski Financial Post Friday, December 24, 2004 Mark Valentine, the former chairman of the bankrupt Thomson Kernaghan & Co. Ltd. brokerage, has been permanently barred from Canada's securities industry as part of a settlement struck with the Ontario Securities Commission. Mr. Valentine, who has been ordered to pay $100,000 to the OSC for investigation costs, was also handed a five-year trading ban. The pact to settle numerous securities-laws violations also prohibits Mr. Valentine from ever serving as a director or officer of any private or public company. "We believe this is probably the most serious sanction the commission has ever meted out in a proceeding," Kelley McKinnon, the OSC's manager of litigation, said in an interview. "That's because Mr. Valentine will never be registered anywhere in Canada again." Mr. Valentine's agreement to never seek securities registration or recognition of any kind applies nationally. He also agreed to never again seek membership in the Investment Dealers Association, the brokerage industry's self-regulatory body. In addition, he has agreed not to serve as a director or an officer of any company as well as subject himself to a trading ban in other Canadian jurisdictions if other provincial regulators demand it. After five years of an outright trading ban, Mr. Valentine will be allowed to trade only Toronto Stock Exchange- and New York Stock Exchange-listed stocks in an account solely in his name. He will not be able to own more than 1% of any class of securities he trades. Those restrictions apply for a further 10 years. The settlement ends a saga that began in the spring of 2001 with financial troubles at Thomson Kernaghan. Thomson Kernaghan collapsed into bankruptcy in July, 2002, about a month after Mr. Valentine was suspended following an internal investigation at the brokerage. Separately, Mr. Valentine was arrested in 2002 in Operation Bermuda Short, a lengthy undercover sting conducted jointly by the RCMP and the U.S. Federal Bureau of Investigation. In March of this year, Mr. Valentine pleaded guilty in the United States to a count of securities fraud and was sentenced to nine months' house arrest to be served in Canada. Mr. Valentine had no comment yesterday. However, Edward Greenspan, the litigator retained by Mr. Valentine, said yesterday his 35-year-old client finished serving his detention last week. "With this settlement agreement, all of the matters over the last several years of his life are now behind him," Mr. Greenspan said in an interview yesterday. "This is the last of it." The OSC's allegations against Mr. Valentine included creating a "culture of conflict of interest and non-compliance" at Thomson Kernaghan through his position as general partner of a number of hedge funds. He also failed to deal fairly and honestly with his clients and placed his interests ahead of theirs, the OSC said. For instance, he sold his clients shares of Chell Corp. for US$2 each, even though he originally received them at US$1 a share a short time before. Mr. Valentine orchestrated "Chell Corp. transactions which provided a substantial benefit to [Thomson Kernaghan's] risk adjusted capital and to his own accounts and which had a corresponding detrimental effect on his clients' account," according to the settlement agreement made public yesterday. Mr. Greenspan said his client will now spend some time to "move forward and reflect in terms of what he wants to do." Asked whether there are civil lawsuits outstanding against Mr. Valentine, Mr. Greenspan responded: "As I understand it, whatever is left is not significant or material." © National Post 2004